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PRKN encodes an E3-ubiquitin-ligase involved in multiple cell processes including mitochondrial homeostasis 
and autophagy. Previous studies reported alterations of mitochondrial function in fibroblasts from patients 
with PRKN mutation-associated Parkinson’s disease (PRKN-PD) but have been only conducted in glycolytic 
conditions, potentially masking mitochondrial alterations. Additionally, autophagy flux studies in this cell 
model are missing.  
We analyzed mitochondrial function and autophagy in PRKN-PD skin-fibroblasts (n=7) and controls (n=13) in 
standard (glucose) and mitochondrial-challenging (galactose) conditions.  
In glucose, PRKN-PD fibroblasts showed preserved mitochondrial bioenergetics with trends to abnormally 
enhanced mitochondrial respiration that, accompanied by decreased CI, may account for the increased 
oxidative stress. In galactose, PRKN-PD fibroblasts exhibited decreased basal/maximal respiration vs. controls 
and reduced mitochondrial CIV and oxidative stress compared to glucose, suggesting an inefficient 
mitochondrial oxidative capacity to meet an extra metabolic requirement. PRKN-PD fibroblasts presented 
decreased autophagic flux with reduction of autophagy substrate and autophagosome synthesis in both 
conditions.  
The alterations exhibited under neuron-like oxidative environment (galactose), may be relevant to the disease 
pathogenesis potentially explaining the increased susceptibility of dopaminergic neurons to undergo 
degeneration. Abnormal PRKN-PD phenotype supports the usefulness of fibroblasts to model disease and the 
view of PD as a systemic disease where molecular alterations are present in peripheral tissues.  
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INTRODUCTION 
 
Parkinson’s disease (PD) has become increasingly 
prevalent as the population ages, being the second most 
prevalent neurodegenerative disorder worldwide [1]. 
Homozygous and compound heterozygous mutations in 
the Parkin gene (PRKN) are the most common cause of 
recessively inherited early-onset PD, accounting for up 
to 50% of familial PD and about 15% of sporadic PD 
(sPD) with disease onset before 45 years [2]. Parkin-
associated PD (PRKN-PD) is clinically similar to sPD 
besides some specific clinical features and the 
significant earlier age of onset, which can occur from 
childhood to the fourth or fifth decade of life [3]. The 
neuropathological hallmark of PRKN-PD is as in sPD, 
the prominent death of dopaminergic neurons (DAn) in 
the substantia nigra pars compacta (SNpc). In contrast, 
the presence of Lewy bodies in PRKN-PD is infrequent 
[3-5]. The etiopathogenesis of PD has been associated 
to several molecular events including mitochondrial 
dysfunction and autophagy impairment [6, 7], which 
may compromise neuronal survival.  
 
The Parkin protein (PRKN) is a multifunctional E3 
ubiquitin ligase that exerts crucial neuroprotective 
functions in DAn [8, 9]. A key role of PRKN in mito-
chondrial macroautophagy (mitophagy) has been 
reported in different models of the disease [10-14]. 
Specifically, upon mitochondrial depolarization there is 
a reduced turnover of the PTEN induced putative kinase 
1 protein (PINK1) and thus, it accumulates in the outer 
mitochondrial membrane leading to the recruitment and 
phosphorylation of PRKN. Subsequently, PRKN 
mediates the polyubiquitination of many outer mito-
chondrial membrane proteins. Briefly, the polyubi-
quitination is the signal for the recruitment of adaptor 
proteins such as p62, which allows the binding of the 
microtubule-associated protein 1 light chain 3 (LC3BII) 
in the forming autophagosome to initiate mitochondrion 
sequestration and the following clearance upon fusion 
with the lysosome [7, 15].  Recent evidence suggests 
that PRKN is also involved in the aggresome-macro-
autophagy pathway in which it promotes the sequestra-
tion of misfolded proteins into aggresomes and its 
consequent clearance by autophagy through p62 and 
LC3BII recruitment [16, 17]. In summary, growing 
evidences point out PRKN as a crucial player in the 
different pathways that consitute macroautophagy 
(hereafter called autophagy). 
 
In this scenario, a number of studies have postulated 
that PRKN-PD may derive from the impaired clearance 
of bioenergetically compromised mitochondria [8, 18] 
and the consequent accumulation of dysfunctional 
mitochondria that trigger an overproduction of intra-  
cellular reactive oxygen species (ROS) that eventually 
may harm cell components. Concurrently, other PRKN 
protein substrates may accumulate [8, 19] within the 
cells, eventually compromising their viability [6, 20]. 
Yet, the precise mechanisms by which PRKN loss-of-
function mutations lead to neurodegeneration remain 
elusive. 
 
A major challenge to study PD is the inaccessible nature 
of the specific neural cell types targeted by the disease 
which are only available only post-mortem. In this 
context, the development of validated models to study 
PD is crucial to enable the understanding of the 
molecular pathways underlying the disease patho-
genesis. On the other hand, there is increasing evidence 
that PD pathology is not confined only in the central 
nervous system (CNS) but is also present in the 
peripheral autonomous nervous system and the organs 
that the latter innervates, including the skin [21]. Skin-
derived fibroblasts are accessible peripheral cells that 
constitute a patient-specific cellular system that retain 
the genetic background of the patients and potentially 
preserve the environmental and cumulative age-related 
events in addition to show relevant expression of most 
PARK genes [22, 23]. Moreover, they can potentially 
recapitulate some pathophysiological features of the 
disease22. In fact, many of the molecular hallmarks 
occurring in PD-DAn have been reported in fibroblasts 
from patients with sporadic and monogenic forms of the 
disease [24-27]. Notwithstanding, previous studies on 
mitochondrial function in PRKN-PD fibroblasts have 
been only conducted in glycolytic conditions in which 
fibroblasts generate most of cell ATP via anaerobic 
glycolysis, thus potentially masking mitochondrial 
alterations present in these cells [28]. In case of PRKN-
PD fibroblasts phenotyping, these studies have reported 
controversial outcomes without assessing, in parallel, 
the cellular impact of PRKN mutations on autophagic 
flux [29-34]. Therefore, growing PRKN-PD fibroblasts 
in a glucose-free medium such as galactose, which has 
been previously used for the diagnosis of primary 
mitochondrial diseases [35, 36], may provide a closer 
approach to the more oxidative metabolism and the 
potential associated mitochondrial function alterations 
present in the DAn of PRKN-PD patients. 
 
In the present study, we aimed to characterize 
mitochondrial function and autophagy in skin-derived 
fibroblasts from PRKN-PD patients in parallel in 
glycolytic (glucose) and mitochondrial-challenging 
conditions (galactose). The identification of alterations 
in PRKN-PD fibroblasts under mitochondrial-challeng-
ing conditions may provide insight into disease patho-
genesis, as the specific neural cell types targeted by the 
disease are predominantly oxidative.  





In order to assess the bioenergetic status of fibroblasts, 
we first performed high-resolution mitochondrial 
respiration analyses. The overall respiratory control 
ratios shown in Figure 1 B-F, are obtained from the 
respiration parameters illustrated in the mitochondrial 
respiratory flux profile (Figure 1A). In glucose, no 
significant differences in the respiratory control ratios 
were found between PRKN-PD and control fibroblasts. 
Even so, trends to increased basal, ATP-linked and 
maximal (uncoupled) respirations and a concomitant 
downward trend in the spare respiratory capacity were 








































In galactose, PRKN-PD fibroblasts exhibited a 
significant decrease in basal/maximal respiratory ratio 
compared to the control fibroblasts. Although the rest of 
parameters were preserved, a downward trend in the 
basal respiration and ATP-linked oxygen consumption 
was shown. Upon changing from glycolytic to 
mitochondrial-challenging conditions, control but not 
PRKN-PD fibroblasts, significantly increased ATP-
linked oxygen consumption and the basal/maximal 
respiratory ratio. In addition, both groups significantly 
decreased the spare respiratory capacity upon changing 
cells from glucose to galactose medium (Figure 1 A-E).  
 
To understand the role of mitochondrial complex I (CI) 
in the overall oxygen consumption, which is reported to 










































Figure 1. Mitochondrial respiratory control ratios in control and PRKN-PD fibroblasts. Illustrative mitochondrial respiration flux 
profile indicating respiratory control parameters (image obtained from Agilent Seahorse XF) (A), basal respiration (B), ATP-linked 
respiration (C), maximal respiration (D), spare respiratory capacity (E) and basal/maximal respiratory ratio (F). In glucose, no significant 
differences were found between PRKN-PD and control fibroblasts in the respiratory control ratios although trends to increased basal and 
maximal as well as ATP-linked respirations and decreased spare respiratory capacity were observed. In galactose, PRKN-PD fibroblasts 
exhibited a significant decrease in basal/maximal respiratory ratio compared to the control fibroblasts as well as a downward trend in the 
basal respiration and ATP-linked respiration. Controls but not PRKN-PD significantly increased oxygen consumption linked to ATP 
production and the basal/maximal respiratory ratio in galactose compared to glucose. Both, control and PRKN-PD fibroblasts significantly 
decreased the spare respiratory capacity upon medium change. Each cell line was seeded in triplicate per condition (n=3 for GLC and n=3 for 
GAL). The results were expressed as means and standard error of the mean (SEM). *= p<0.05. CTL= Control fibroblasts. GAL= 10 mM galactose 
medium. GLC= 25 mM glucose medium. NS= not significant. OCR= Oxygen consumption rate. PRKN-PD= Parkin-associated PD fibroblasts. 
Respiratory control ratios were normalized by total protein content and by citrate synthase activity as a marker of mitochondrial content. 
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through the specific oxidation of CI-substrates, pyruvate 
and malate (PMox). Although we did not obtain 
statistically significant differences, PRKN-PD showed a 
strong non-significant downward trend in CI-stimulated 
oxygen consumption compared to control fibroblasts in 
glucose. Exposure to galactose trended to reduce CI-
stimulated oxygen consumption in control, but not in 

















































Mitochondrial respiratory chain enzymatic activities 
 
We next wanted to determine if the differences 
observed in mitochondrial respiration analysis between 
PRKN-PD and control fibroblasts were reflected in the 
enzymatic activities of the Mitochondrial respiratory 
chain (MRC) complexes. Although no significant diffe-
rences were obtained between groups, the same pattern 
















































Figure 3. Mitochondrial respiratory chain (MRC) enzymatic activities in control and PRKN-PD fibroblasts. Enzymatic 
activities of the complexes I (A), II+III (B) and CIV (C) of the MRC. No significant differences were obtained between groups. Exposure to 
galactose significantly reduced CI-enzymatic activity of control fibroblasts and significantly decreased CIV enzymatic activity of PRKN-PD 
fibroblasts when compared to glucose. The results were expressed as means and standard error of the mean (SEM). *= p<0.05. CTL= 
Control fibroblasts. GAL= 10 mM galactose medium. GLC= 25 mM glucose medium. NS= not significant. PRKN-PD= Parkin-associated PD 
fibroblasts. Enzymatic activity values were normalized by citrate synthase activity as a marker of mitochondrial content. 
 
Figure 2. Complex I-stimulated oxygen consumption through pyruvate and malate oxidation measurement 
in control and PRKN-PD fibroblasts. No statistically significant differences were obtained between groups. In glucose, 
down-ward trends in CI-stimulated oxygen was shown in PRKN-PD compared to control fibroblasts. Exposure to galactose 
trended to reduce CI-stimulated oxygen consumption in control fibroblasts when compared to glucose, but not in PRKN-
PD cells. The results are expressed as means and standard error of the mean (SEM). CTL= Control fibroblasts. GAL= 10 mM 
galactose medium. GLC= 25 mM glucose medium. NS= not significant. PRKN-PD= Parkin-associated PD fibroblasts. Oxygen 
consumption values were normalized by citrate synthase activity as a marker of mitochondrial content. 
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reflected in CI enzymatic activity, where PRKN-PD 
showed a strong downward trend compared to control 
fibroblasts in glucose. Exposure to galactose significantly 
reduced CI-enzymatic activity of controls, but not 
PRKN-PD fibroblasts, when compared to glucose, in 
accordance to CI-stimulated oxygen consumption results. 
In addition, exposure to galactose significantly decreased 
CIV enzymatic activity in PRKN-PD fibroblasts when 




Lipid peroxidation was measured as an indicator of 
ROS-derived oxidative damage. As illustrated in Figure 
4, PRKN-PD exhibited an upward trend in lipid 
peroxidation compared to control fibroblasts in glucose, 
while exposure to galactose significantly reduced oxida-
































Mitochondrial membrane potential  
 
Given that a correct mitochondrial polarization is 
crucial for mitochondrial integrity, we measured 
mitochondrial membrane potential in control and 
PRKN-PD fibroblasts. No significant differences in 
mitochondrial membrane potential were obtained 
between groups. However, upon galactose exposure, 
control fibroblasts trended to enhance mitochondrial 
membrane potential as compared to glucose, while 






































Mitochondrial network complexity  
 
Mitochondrial function is a process intimately 
associated with changes in mitochondrial dynamics 
[37]. For this reason, we assessed mitochondrial length 
Aspect ratio (AR) and branching Form factor (FF) in 
control and PRKN-PD fibroblasts and found it was 
comparable between groups in both media (Supplemen-




We next evaluated mitochondrial content through the 
assessment of Mitochondrial DNA (mtDNA) copy 
number,  citrate synthase activity (CS) and mitochondrial 
 
Figure 4. Oxidative stress measured through lipid 
peroxidation in control and PRKN-PD fibroblasts. In 
glucose, PRKN-PD exhibited an upward trend in lipid 
peroxidation compared to control fibroblasts while exposure to 
galactose significantly reduced oxidative stress levels in PRKN-PD 
compared to glucose. The results are expressed as means and 
standard error of the mean (SEM). *= p<0.05. CTL= Control 
fibroblasts. GAL= 10 mM galactose medium. GLC= 25 mM 
glucose medium. PRKN-PD= Parkin-associated PD fibroblasts. 
 
Figure 5. Mitochondrial membrane potential in control 
and PRKN-PD fibroblasts. Mitochondrial membrane potential 
is represented as the ratio of red vs. green fluorescence signals of 
JC-1 representing the cells with correctly polarized vs the cells 
with depolarized mitochondria. No significant differences in 
mitochondrial membrane potential were obtained between 
groups. Upon galactose exposure, control fibroblasts trended to 
enhance mitochondrial membrane potential as compared to 
glucose, while PRKN-PD fibroblasts remained unchanged. The 
results are expressed as means and standard error of the mean 
(SEM). AU= Arbitrary units. CTL= Control fibroblasts. GAL= 10 mM 
galactose medium. GLC= 25 mM glucose medium. JC-1: 5,5’,6,6’-
tetrachloro-1,1’,3,3’-tetraethylbenzimidazol-carbocyanine iodide. 
NS= not significant. PRKN-PD= Parkin-associated PD fibroblasts. 






















network and found that all parameters were preserved 




To ascertain the potential impact of PRKN mutations on 
autophagy we quantified p62 and LC3BII protein levels. 
PRKN-PD fibroblasts presented significant lower basal 
levels of p62 and LC3BII in both media compared to 
controls as shown in Figure 7A and B (0h).  
 
The processes of autophagosome synthesis and 
degradation are spatially and temporally separated. In 
order to determine whether the decrease in basal p62 
and LC3BII protein levels was due to a reduction in 
autophagosome synthesis or to a later stage in the path-
way such as autophagosome degradation, we treated 
cells with bafilomycin A1. Bafilomycin A1 clamps 
fusion of autophagosomes with lysosomes and thus 
blocks autophagosome degradation, allowing measure-
ment of autophagosome synthesis, whereas both synthe-
sis and degradation occur in the untreated samples. The 
degradation rate can be deduced by subtracting LC3BII 
levels in the untreated samples from those treated with 
bafilomycin A1 [38]. 
 
In both groups, p62 and LC3BII levels were 
significantly increased at 4 and 8 hours under bafilo-
mycin A1 treatment compared to basal state, indicating 
some extent of autophagic flux in both media. However, 
in glucose, p62 and LC3BII levels at 4 and 8 hours of 
treatment were significantly lower in PRKN-PD com-
pared to control fibroblasts and the same trends were 
observed in galactose (Figure 7 A and B; 4h and 8h). 






















PD fibroblasts, showed significantly decreased basal 
levels of both molecules compared to glucose with 
concurrent   significantly decreased p62 and conserved 
LC3BII protein levels upon bafilomycin A1 treatment, 





We finally investigated cell growth rates in control and 
PRKN-PD fibroblasts in glucose and galactose media to 
assess how PRKN mutations impact on the overall 
cellular health. Although not significantly, PRKN-PD 
fibroblasts showed downward trend in cell growth rate 




To our knowledge, this is the first study exploring the 
mitochondrial phenotype and the autophagic print in 
mitochondrial-challenging conditions (galactose) in 
skin-derived fibroblasts from PRKN-PD patients. Our 
results suggest that mitochondrial dysfunction and 
impaired autophagic flux are present in non-neural 
peripheral tissues of PRKN-PD patients. In addition, the 
alterations that PRKN-PD fibroblasts exhibited under 
mitochondrial-challenging conditions may be relevant 
to disease pathogenesis taking into consideration that 
the target tissue of the disease is predominantly 
oxidative.  
 
To date, previous studies reporting altered mito-
chondrial homeostatic function in PRKN-PD fibro-
blasts have reported controversial results. Remarkably, 
all these studies were performed in glycolytic con-
Figure 6. Mitochondrial content in control and PRKN-PD fibroblasts. Mitochondrial content was measured through mtDNA copy 
number (A), citrate synthase enzymatic activity (B) and mitochondrial network (C). Comparable mitochondrial content was observed 
between groups in both media. The results are expressed as means and standard error of the mean (SEM). CTL= Control fibroblasts. GAL= 
10 mM galactose medium. GLC= 25 mM glucose medium. mtDNA= mitochondrial DNA. PRKN-PD= Parkin-associated PD fibroblasts.  
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ditions that may partially unveil mitochondrial deficits 
[29-34]. In this sense, we first explored the mito-
chondrial function phenotype in glucose conditions and 
did not find any statistically significant difference 
between PRKN-PD and control fibroblasts. Interestingly, 
we found abnormal trend to increased overall 
mitochondrial respiration in PRKN-PD. More specifical-
ly, we observed a bias towards increased mitochondrial 
basal, ATP-linked and maximal respirations, as likewise 
reported by previous authors [31, 32]. In contrast to these 
findings, a previous study that was performed with a 
different respirometry approach, described an overall 
decrease in all the aforementioned mitochondrial 










































To understand if the increased respiration in PRKN-PD 
cells was physiologically healthy, we assessed 
mitochondrial CI function as alterations at this level 
have been described in the CNS and in peripheral 
tissues of PD patients [33, 39, 40]. Although not 
statistically significant, we observed a strong downward 
decline in CI-stimulated oxygen consumption, which 
accordingly translated into a decreased CI enzymatic 
activity in PRKN-PD fibroblasts in glucose. In 
accordance with our results, Pacelli et al. and Mortiboys 
et al. [29, 33] described CI enzymatic decline in PRKN-
PD fibroblasts, while Grünewald et al. observed 
preserved CI function in isolated mitochondria from a 












































Figure 7. Autophagic flux in control and PRKN-PD fibroblasts. p62 (A) and LC3BII (B) protein levels at basal (0h) and under 
bafilomycin A1 treatment (4 or 8h) in glucose and galactose media. Basal levels p62 and LC3BII were significantly decreased in PRKN-PD 
compared to control fibroblasts in both media. PRKN-PD fibroblasts presented significantly lower p62 and LC3BII levels after 4 and 8 
hours of treatment compared to controls in glucose and the same tendency was obtained in galactose. Exposure to galactose significantly 
decreased basal levels of both molecules compared to glucose in controls, but not in PRKN-PD fibroblasts. Controls, but not PRKN-PD, 
also showed significantly reduced p62 in front of conserved LC3BII protein levels upon treatment. Asterisks above the bars indicate 
statistically significant differences between protein levels at basal (0h) and after of bafilomycin A1 treatment (4 or 8h) within a group. The 
results are expressed as means and standard error of the mean (SEM). Asterisk brackets indicate statistically significant differences 
between CTL and PRKN-PD fibroblasts. Bold asterisk brackets indicate statistically significant differences between media. GAL= 10 mM 
galactose medium. GLC= 25 mM glucose medium. PRKN-PD= Parkin-associated PD fibroblasts.  
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rate increased mitochondrial respiration and the 
decreased MRC CI function in glucose is still a matter 
of debate but may correspond to an attempt of the 
PRKN-PD cell to overcome an inefficient oxidative 
phosphorylation (OXPHOS) function, mainly evidenced 




























To evaluate efficiency of the OXPHOS function, we 
measured oxidative damage which is a hallmark of 
mitochondrial dysfunction and has often been related 
with neurodegeneration and specifically with PD [6, 41, 
42]. In accordance, we observed a non-significant 
strong upward trend in lipid peroxidation in the PRKN-
PD group in glucose. This moderate increase in 
oxidative damage could be related to MRC malfunction 
in PRKN-PD fibroblasts suggested by both the abnor-
mal increased mitochondrial respiration and CI 
dysfunction, considering CI a major source of ROS 
[43]. In line with our results, other authors demonstrated 
increased protein and lipid oxidation in smaller cohorts 
[29, 34].  
 
PRKN has been implicated in mitochondrial biogenesis 
[44]. In this context, we assessed mitochondrial content 
and observed it was preserved in PRKN-PD cells 
irrespective of the media, in accordance with Mortiboys 
et al. [33]. We cannot rule out that preserved PRKN-PD 
mitochondrial content may be triggered by an impair-
ment of the mitochondrial turnover (mitophagy) in these 
cells that could counteract the lack of mitochondrial 
biogenesis. In contrast to our findings, Grunewald et al. 
reported increased mitochondrial content through an 
enhancement of the CS activity in isolated mitochondria 
of PRKN-PD fibroblasts as a compensa-tory effect for 
the mild mitochondrial dysfunction observed in these 
cells [34], whereas Pacelli et al. showed a decrease in 
this parameter [29]. Similarly, there is considerable 
controversy in regards of mitochondrial network 
morphology in PRKN-PD fibroblasts [29-34], although 
Parkin has been reported to be involved in mito-
chondrial dynamics [45]. In line with previous studies, 
we failed to demonstrate significant alterations in 
mitochondrial network morphology of PRKN-PD in 
neither of the media [30, 31, 34] despite the specific 
effectors of mitochondrial dynamics were not analyzed 
in the present work. Notwithstanding, a previous study 
reported decreased mitochondrial branching in PRKN-
PD fibroblasts [32].  
 
One of the main contributions of the present work is to 
evaluate the phenotype of PRKN-PD fibroblasts in 
mitochondrial-challenging conditions. Whereas the 
glycolytic metabolism of glucose forms pyruvate 
yielding 2 net ATP, the production of pyruvate via 
glycolytic metabolism of galactose yields no net ATP 
production, forcing the cells to rely on mitochondrial 
oxidative metabolism to obtain the vast majority of the 
cell ATP28 and approaching them somehow the 
neuronal metabolism. Moreover, replacing glucose with 
galactose medium has long been used to diagnose 
primary mitochondrial diseases in cells derived from 
patients with OXPHOS deficiencies [35, 36]. This is 
the first study reporting that the exposition of PRKN-
PD fibroblasts to oxidative conditions uncovers a 
differential mitochondrial function phenotype respect to 
standard glycolytic conditions. We specifically found a 
significant decrease in the mitochondrial basal/maximal 
respiratory ratio in galactose, which indicates that upon 
an increasing ATP demand that can only be confronted 
through enhancing mitochondrial metabolism, PRKN-
PD cells cannot respond as controls do. Accordingly, 
we found downward trends in basal and ATP-linked 
respirations as well as in mitochondrial membrane 
potential in PRKN-PD compared to controls. In this 
line, Mortiboys et al. previously described decreased 
mitochondrial membrane potential in fibroblasts from 
five PRKN-PD patients in galactose [33]. Consistent 
with these results, we found a decline in mitochondrial 
CIV function and oxidative stress in PRKN-PD 
fibroblasts that was evident upon growing cells in 
galactose. Previous studies reported mitochondrial CIV 
deficiency in two PRKN-PD fibroblasts lines [29], 
while others have reported unaltered enzymatic activity 
of this complex in glucose medium [33, 34].  
 
Figure 8. Cell growth rate in control and PRKN-PD 
fibroblasts. Although not significant, PRKN-PD fibroblasts 
showed downward trend in cell growth rate in both media. The 
results are expressed as means and standard error of the mean 
(SEM). AU= Arbitrary units. CTL= Control fibroblasts. GAL= 10 
mM galactose medium. GLC= 25 mM glucose medium. PRKN-
PD= Parkin-associated PD fibroblasts.  
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The second main finding of this study is the description 
of autophagic alterations in PRKN-PD fibroblasts. 
Specifically, we observed significant lower levels of 
both the autophagy substrate (p62) and autophagosome 
content markers (LC3BII) in PRKN-PD fibroblasts at 
basal and after inhibiting autophagosome fusion with 
lysosomes in both media. These findings suggest that 
the overall autophagic flux is decreased in PRKN 
mutant fibroblasts. PRKN-PD fibroblasts did not exhibit 
changes in autophagic flux upon exposure to galactose 
as compared to glucose. Contrarily, our results suggest 
that galactose enhances autophagic flux in controls. 
Although p62 levels decreased in controls upon 
treatment when compared to glucose, p62 can be 
degraded through autophagosome-independent me-
chanisms such as the ubiquitin-proteasome system [46, 
47], and thus, may partially evade bafilomycin A1 
treatment. The disruption in the autophagosome-
lysosome pathway observed in PRKN-PD fibroblasts 
may promote accumulation of PRKN substrates 
including defective mitochondria and misfolded and 
aggregated proteins that, in physiologic conditions, 
should instead be degraded by the autophagic 
machinery. Thus, further research should be undertaken 
to investigate the role of autophagic disruption in 
PRKN-PD ethiopathogenesis. 
 
In summary, exposure to galactose uncovered a 
differential mitochondrial phenotype in PRKN-PD 
fibroblasts compared to glycolytic medium while 
authopagic flux was reduced in these cells, irrespective 
of the culture medium. In addition, galactose suggested 
to enhance both mitochondrial function and autophagy 
in controls, by improving above all mitochondrial 
respiration performance and increasing autophagosome 
degradation. This improvement was not observed in 
PRKN-PD fibroblasts and may explain overall cell 
health decay evidenced in PRKN-fibroblasts by trends 
towards reduced cell growth. As neurons constitute a 
post-mitotic tissue that strongly relies on mito-
chondrial oxidative metabolism and autophagy to meet 
their high energy needs, alterations in these cell 
processes make them particularly vulnerable. Thus, the 
mitochondrial phenotype and the autophagic flux 
alterations exhibited by PRKN-PD fibroblasts under 
oxidative conditions may be of relevance to disease 
pathogenesis.  
 
Notwithstanding, our study contains some limitations. 
First, despite being the study with a larger sample size 
respect to previous, sample size of our cohort is still 
limited. Second, the inherent individual variability 
present in the samples may also contribute to hinder 
inter-group statistical differences. Also, methodological 
issues amongst studies may support discrepancies. For  
instance, the use of different high-resolution respire-
metry approaches in which oxygen consumption is 
measured from seeding fibroblasts or from cells in 
suspension. Similarly, assessing MRC enzymatic 
activities in intact cells or in mitochondrial enriched 
fractions may contribute to outcome disparities. Third, 
although mitochondrial function has been previously 
reported as a critical regulator of autophagy in euka-
ryotic cells [48, 49], the link between mitochondrial 
function and autophagy alterations in PRKN-PD 
fibroblasts is not herein explored. In this regard, future 
mechanistic studies in this field may be helpful in 
clarifying this issue. Finally, we acknowledge that many 
other mechanisms may be underlying the ethio-
pahtology of PD, where the loss of DAn may be the 
common eventual manifestation of this heterogeneous 
disease. 
 
In conclusion, our work supports the view of PD as a 
systemic disease where mitochondrial and autophagic 
alterations play a role also in non-neural peripheral 
tissues such as skin fibroblasts, and encourages further 
studies in this model. The alterations that PRKN-PD 
fibroblasts exhibit under mitochondrial-challenging 
conditions may be relevant to disease pathogenesis and 
may be related to the increased susceptibility of patient 
DAn, which are predominantly oxidative, to undergo 
degeneration. Future studies with larger sample sizes 
and different PRKN-PD cohorts are warranted to 
confirm the results herein reported.  
 
MATERIALS AND METHODS 
 
Subjects and PRKN mutational screening 
 
We recruited seven PD patients carrying mutations in 
the PRKN gene (PRKN-PD, n=7), and thirteen 
unrelated healthy subjects (CTL, n=13) among patients 
and relatives visiting the Movement Disorders 
outpatient clinic from the Hospital Clínic of Barcelona 
(Barcelona, Spain). PRKN-PD patients were diagnosed 
according to the UK Brain Bank criteria [50] and the 
mutational screening of the PRKN gene was performed 
as previously described [51]. Clinical and epi-
demiological data of PRKN-PD patients is summarized 
in Table 1. Gender and age-paired control group 
included six males and seven female subjects with an 
age range of 35-86 years and with a mean age of 58 
years. Subjects with comorbidities, mitochondrial 
disorders, and those consuming mitochondrial toxic 
drugs were excluded from the study [52]. The study was 
approved by the ethics committee of the Hospital Clínic 
of Barcelona, following the guidelines of Helsinki 
declaration, and subjects were included in the study 
after signing the informed consent form.  


































Cell culture  
 
Fibroblasts were obtained by a 6 mm of diameter punch 
skin biopsy from the alar surface of the non-dominant 
arm of the subjects. Fibroblasts were cultured first in 
DMEM with high glucose (25 mM) supplemented with 
10% (v/v) heat-inactivated fetal bovine serum and 1% 
(v/v) L-glutamine and penicillin/ streptomycin at 37ºC 
and 5% CO2 until 80-90% optimal confluence was 
reached. Each cell line was then exposed in parallel to 
25 mM glucose (standard) or 10 mM galactose 
(mitochondrial-challenging) media for 24 hours [28, 53-
55]. Fibroblasts were harvested for further analyses as 
reported elsewhere [56]. All functional assays were 
performed in cells between passage 5 and 10. 
 
Mitochondrial respiration analysis 
 
Mitochondrial oxygen consumption rates 
Oxygen consumption rates (OCRs) were measured in 
intact adherent fibroblasts through Agilent Seahorse 
XFe24 Analyzer (Seahorse Bioscience). Briefly, 

































tomized 24-well Seahorse cell culture plates and left to 
adhere overnight in 250 uL of growth medium. Each 
cell line was seeded in triplicate per condition (n=3 for 
glucose and n=3 for galactose). After 24 hours, growth 
medium was removed and wells were washed and 
replaced with Seahorse XF Base Medium (Seahorse 
Bioscience) containing either 25 mM glucose or 10 mM 
galactose plus 1 mM sodium pyruvate and 1 mM 
glutamine. Afterwards, plates were incubated for 30 
min at 37 °C without CO2 according to manufacturer’s 
protocol. In order to determine the different respiratory 
control ratios, oxygen consumption was measured under 
basal conditions and after the addition of oligomycin, 
which blocks ATP synthase allowing the assessment 
of the natural proton leak across the inner 
mitochondrial membrane (IMM). This was followed 
by the addition of the uncoupler carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP) to measure 
the maximal respiratory capacity. FCCP is an ionophore 
that directly transports protons across the IMM 
bypassing the ATP synthase proton channel thus 
leading to a rapid consumption of oxygen without the 
ATP generation. Finally, complex I and III inhibitors, 
rotenone and antimycin-A, were added to assess 








Age of disease 
onset 
 




PRKN-PD 1 Heterozygous PRKN val15met Male 47 57 L-Dopa 
PRKN-PD 2 
Homozygous PRKN exon 2-3-4 
deletion 
Male 35 69 L-Dopa 
PRKN-PD 3 Homozygous PRKN exon 5-6 deletion Female 27 63 L-Dopa 
PRKN-PD 4 
Compound heterozygous PACRG 
exon 1 deletion/ PRKN exon 6 
deletion 
Female 8 35 L-Dopa 
PRKN-PD 5 
Compound heterozygous PRKN exon 
2 duplication/ exon 6 deletion 
Male 20 49 L-Dopa 
PRKN-PD 6 Homozygous PRKN exon 3 deletion Male 25 48 L-Dopa 
PRKN-PD 7 
Compound heterozygous PRKN exon 
6 deletion/ exon 8 deletion 
Female 38 44 L-Dopa 
No differences in mean age and gender were found between PRKN-PD and CTL subjects. Control group included six males and 
seven female subjects with an age range of 35-86 years and with a mean age of 58 years. CTL= healthy control subjects (not 
affected by PD or any PRKN mutation). PACRG=Parkin coregulated gene. PRKN-PD= Parkin-associated Parkinson’s disease. 
Val15Met= Methionine to Valine substitution at position 15. 
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unspecific non-mitochondrial respiration (all reagents 
from Sigma-Aldrich). In addition, spare respiratory 
capacity and basal/maximal respiratory ratio were 
calculated as the maximal after basal OCR subtraction 
expressed in percentage, and the ratio between basal 
and maximal OCRs, respectively. All respiration values 
were normalized to total cell protein content 
determined in each well through the bicinchoninic acid 
assay (BCA) assay according to manufacturer’s 
protocol (Thermo Scientific) and CS activity (see 
mitochondrial respiratory chain enzymatic activities 
method section). 
 
Mitochondrial complex I-stimulated oxygen 
consumption  
To assess oxygen consumption under the stimulation of 
mitochondrial CI, 1 million of fibroblasts were obtained 
and resuspended in ice-cold respiration MiR05 medium. 
High-resolution respirometry was performed in 
digitonin-permeabilized cells using OroborosTM 
Oxygraph-2k system® (Innsbruck, Austria) and 
oxidation of CI substrates, pyruvate and malate (PMox), 
was monitored following manufacturer’s protocol [56, 
57]. Results were normalized to cell number and CS 
activity (see mitochondrial respiratory chain enzymatic 
activities method section). 
 
Mitochondrial respiratory chain enzymatic activities 
 
In order to study mitochondrial respiratory chain 
(MRC) function, enzymatic activities of mitochondrial 
complexes I (CI), II+III (CII+III) and IV (CIV) were 
spectrophotometrically measured at 37ºC in fibroblasts, 
as reported elsewhere [58, 59]. CS activity was also 
spectrophotometrically determined at 37ºC in fibro-
blasts, as it is considered a reliable marker of 
mitochondrial content [60]. Mitochondrial content was 
further confirmed by alternative methods (see 
mitochondrial content method section). 
 
All enzymatic assays were performed following 
national standardized methods and were run in parallel 
with internal quality controls [58]. Changes in 
absorbance were registered in a HITACHI U2900 
spectrophotometer through the UV-Solution software 
v2.2 and were expressed as nanomoles of consumed 
substrate or generated product per minute and milligram 
of protein (nmol/minute·mg protein). All enzymatic 




Lipid peroxidation levels are indicative of the ROS-
derived oxidative damage in cell lipid compounds. 
Lipid peroxidation was quantified using the 
BIOXYTECH® LPO-586™ colorimetric assay (Oxys 
International Inc., CA, USA). Specifically, the levels of 
malondialdehyde (MDA) and 4-hydroxyalkenal (HAE) 
which are peroxides derived from fatty acid oxidation, 
were quantified in duplicate through spectrophotometry. 
The results were next normalized by protein content and 
expressed as μM MDA+ HAE/mg protein, as previously 
reported [61]. 
 
Mitochondrial membrane potential 
 
Mitochondrial membrane potential of fibroblasts was 
assessed in a BD FACSCaliburTM cell analyzer (BD 
Biosciences) by JC-1 potentiometric dye and both, 
green (~525 nm) and red (~590 nm) fluorescent 
emissions of each cell population were simultaneously 
monitored by flow cytometry, as reported elsewhere 
[62, 63]. Results were obtained as percentage of cells 
with specific fluorescence indicating polarized or 
depolarized mitochondria. We calculated the red/green 
ratio indicating the ratio between correctly polarized 
and depolarized mitochondria, whose decrease indicates 
mitochondrial depolarization. 
 
Mitochondrial network complexity analysis 
 
Mitochondrial content and mitochondrial network 
complexity were assessed by immunochemistry and 
confocal microscopy as reported elsewhere [56, 64]. A 
minimum of 3 fibroblasts from each subject were 
visualized and analysed using the Image J software and 
a macro of instructions was used to perform semi-
automatic quantitation [65]. Mitochondrial network of 
each cell was subjected to particle analysis and the 
following parameters were assessed: aspect ratio (AR) 
(major axis/minor axis), form factor (FF), which was 
calculated as the inverse of the circularity (4π·area/ 
perimeter2) and, mitochondrial network or content (total 
number of mitochondria/total cell area). AR and FF 
values correspond to mitochondrial length and 
branching, respectively, and are considered parameters 
of mitochondrial health. AR and FF values of 1 are 
indicative of circular unbranched mitochondria which 
are a sign of pathologic mitochondrial isolation. As 
mitochondria elongate and become more branched, AR 




The following three approaches were used to quantify 
mitochondrial content in fibroblasts: 
 
Mitochondrial DNA (mtDNA) copy number  
Total DNA from fibroblasts was isolated through the 
standard phenol–chloroform extraction procedure as 
previously reported [66]. To assess mitochondrial DNA 
(mtDNA) content, fragments of the highly conserved 
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mitochondrial 12S rRNA gene and the constitutive 
nuclear ribonuclease P gene (RNase P) were amplified 
in triplicates by multiplex qRT-PCR using Applied 
Biosystems technology [67]. mtDNA content was 
expressed as the ratio between the 12S rRNA and 
RNase P genes. 
 
Citrate synthase enzymatic activity 
CS activity was spectrophotometrically determined in 
fibroblasts (see mitochondrial respiratory chain 
enzymatic activities method section). 
 
Determination of mitochondrial network  
Immunochemistry and confocal microscopy were 
performed to quantify mitochondrial network or content 
and expressed as the total number of mitochondria per 
total cell area (see mitochondrial network complexity 
analysis method section) [68]. In general, higher 
mitochondrial network values are considered sign of 
healthy mitochondria. 
 
Autophagic flux analysis 
 
Where indicated, cells were treated with 0.1 µM 
bafilomycin A1 (Sigma) for 4 and 8 hours at 37°C in 
the presence of 5% CO2. Bafilomycin A1 is a proton 
pump inhibitor that neutralizes lysosomal pH preventing 
fusion of autophagosomes with lysosomes and thus 
allowing monitoring of autophagosome synthesis [38]. 
Briefly, fibroblasts were lysed with RIPA buffer 
(Sigma) plus protease inhibitor cocktail (Thermo 
scientific) followed by shaking and centrifugation at 
16,100 g at 4°C for 10 minutes. Soluble fractions were 
kept at -80 °C until western blot analysis. Electro-
phoresis and blotting were performed, as reported 
elsewhere [56, 62]. Blots were probed with anti-
SQSTM1/p62 (Abcam) and anti-LC3B (Cell Signaling) 
antibodies. LC3BII is considered a marker of 
autophagosome number and p62 is an ubiquitin-
binding scaffold protein that labels molecules and 
organelles that need to be degraded acting as a cargo 
receptor that is recruited to autophagosomes through 
LC3BII inter-action [69]. Total protein content was 
obtained through SYPRO Ruby Protein Blot Stain, 
according to manufacturer’s protocol (Molecular 
Probes). The intensity of signals was quantified by 
densitometric analysis (Image Quant TL Software, GE 
Healthcare). Results were expressed as p62 and LC3BII 
protein levels normalized by the total cell protein 
content [70].  
 
Cell growth  
 
Cell growth rate was manually determined through cell 
counting with the Neubauer chamber using trypan blue 
staining at the times of seeding and harvesting the cells 
















Statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS, version 19) 
software (IBM SPSS Statistics; SPSS Inc). Differences 
amongst groups were sought by non-parametric tests 
after filtering for outlier values in the datasets. 
Specifically, Kruskal-Wallis and Mann–Whitney U 
statistical tests for independent samples were used when 
required. Significance was accepted for asymptotic 2-
tailed p-values below 0.05 (for a confidence interval of 
α= 95%). Results were expressed as means ± the 
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Supplementary Figure 1. Mitochondrial network complexity in control and PRKN-PD fibroblasts. Mitochondrial 
length (aspect ratio) (A) and mitochondrial branching (form factor) (B) were comparable between groups in both media. The 
results are expressed as means and standard error of the mean (SEM). GAL= 10 mM galactose medium. GLC= 25 mM glucose 
medium. PRKN-PD= Parkin-associated PD fibroblasts.  
 
